Differential Expression of MUC12, MUC16, and MUC20 in Patients with Active and Remission Ulcerative Colitis

Background. Patients with UC have shown an important defect in the secretion and maintenance of the mucosal barrier as part of inadequate expression of mucin genes. The aim of the present study was to determine the expression of MUC12, MUC16, and MUC20 in colonic tissue from patients with UC in regard to their clinical outcomes.Methods. We included a total of 40 patients with UC and 30 normal controls. Mucin gene expression was performed by RT-PCR and protein expression was detected by immunohistochemistry.Results. Patients with active UC showed no significant expression of MUC12 gene in mucosa compared to the group of patients with UC in remission and the normal control group. MUC16 gene expression was significantly increased in the UC active and remission groups compared to the normal control group (P=0.03). MUC20 gene expression was found significantly decreased in patients with active UC compared to both remission group (P=0.001) and normal controls (P=0.001). Furthermore, an association was found between MUC20 gene expression and the presence of histological remission in patients with UC (P=0.003, OR = 0.37).Conclusions. An increased gene expression of MUC16 and MUC20 was found in patients with remission UC.

Download Full-text

Study on potential differentially expressed genes in stroke by bioinformatics analysis

Neurological Sciences ◽

10.1007/s10072-021-05470-1 ◽

2021 ◽

Author(s):

Xitong Yang ◽

Pengyu Wang ◽

Shanquan Yan ◽

Guangming Wang

Keyword(s):

Gene Expression ◽

Differentially Expressed Genes ◽

Normal Control ◽

Enrichment Analysis ◽

Normal Control Group ◽

Control Group ◽

Ppi Network ◽

Hub Genes ◽

Pathway Enrichment ◽

Key Genes

AbstractStroke is a sudden cerebrovascular circulatory disorder with high morbidity, disability, mortality, and recurrence rate, but its pathogenesis and key genes are still unclear. In this study, bioinformatics was used to deeply analyze the pathogenesis of stroke and related key genes, so as to study the potential pathogenesis of stroke and provide guidance for clinical treatment. Gene Expression profiles of GSE58294 and GSE16561 were obtained from Gene Expression Omnibus (GEO), the differentially expressed genes (DEGs) were identified between IS and normal control group. The different expression genes (DEGs) between IS and normal control group were screened with the GEO2R online tool. The Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses of the DEGs were performed. Using the Database for Annotation, Visualization and Integrated Discovery (DAVID) and gene set enrichment analysis (GSEA), the function and pathway enrichment analysis of DEGS were performed. Then, a protein–protein interaction (PPI) network was constructed via the Search Tool for the Retrieval of Interacting Genes (STRING) database. Cytoscape with CytoHubba were used to identify the hub genes. Finally, NetworkAnalyst was used to construct the targeted microRNAs (miRNAs) of the hub genes. A total of 85 DEGs were screened out in this study, including 65 upward genes and 20 downward genes. In addition, 3 KEGG pathways, cytokine − cytokine receptor interaction, hematopoietic cell lineage, B cell receptor signaling pathway, were significantly enriched using a database for labeling, visualization, and synthetic discovery. In combination with the results of the PPI network and CytoHubba, 10 hub genes including CEACAM8, CD19, MMP9, ARG1, CKAP4, CCR7, MGAM, CD79A, CD79B, and CLEC4D were selected. Combined with DEG-miRNAs visualization, 5 miRNAs, including hsa-mir-146a-5p, hsa-mir-7-5p, hsa-mir-335-5p, and hsa-mir-27a- 3p, were predicted as possibly the key miRNAs. Our findings will contribute to identification of potential biomarkers and novel strategies for the treatment of ischemic stroke, and provide a new strategy for clinical therapy.

Download Full-text

Effect of GDM on the Expression of MT1-MMP and u-PA in Glioma Cells

Advanced Materials Research ◽

10.4028/www.scientific.net/amr.1033-1034.220 ◽

2014 ◽

Vol 1033-1034 ◽

pp. 220-223

Author(s):

Xue Mei Han ◽

Li Bo Wang ◽

Ni Ni Li ◽

Song Yan Liu

Keyword(s):

Normal Control ◽

Glioma Cell ◽

Fetal Bovine Serum ◽

Glioma Cells ◽

Normal Control Group ◽

Control Group ◽

Rt Pcr ◽

Glioma Cell Lines ◽

Fetal Bovine ◽

Identify Gene Expression

To examine the effect of GDM on the expression of MT1-MMP and u-PA genes in glioma cells. Glioma cell lines U251 and U87 were cultured in DMEM medium supplemented with 10% fetal bovine serum. RT-PCR was used to identify gene expression level. The level of u-PA mRNA was up-regulated significantly in the HGF group compared with the normal control group (P<0.05). The expression of MT1-MMP and u-PA was significantly lower in the GDM group than in the normal control and HGF groups (P<0.05). The expression of u-PA in the HGF+GDM group was down-regulated significantly compared with the normal control and HGF groups (P<0.05).GDM can inhibit expression of both MT1-MMP and u-PA in glioma cells.

Download Full-text

Identification of Hub Genes Associated with Development of Lung Adenocarcinoma by Integrated Bioinformatics Analysis

10.21203/rs.3.rs-550498/v1 ◽

2021 ◽

Author(s):

Jinglei Li ◽

Wei Hou

Keyword(s):

Gene Expression ◽

Survival Analysis ◽

Network Analysis ◽

Lung Adenocarcinoma ◽

Normal Control ◽

Gene Expression Analysis ◽

Normal Control Group ◽

Control Group ◽

Differential Gene Expression Analysis ◽

Differential Gene

Abstract Purpose: Lung adenocarcinoma (LUAD) has high heterogeneity and poor prognosis, posing a major challenge to human health worldwide. Therefore, it is necessary to improve our understanding of the molecular mechanism of LUAD in order to be able to better predict its prognosis and develop new therapeutic strategies for target genes.Methods: The Cancer Genome Atlas and Gene Expression Omnibus, were selected to comprehensively analyze and explore the differences between LUAD tumors and adjacent normal tissues. Critical gene information was obtained through weighted gene co-expression network analysis (WGCNA), differential gene expression analysis, and survival analysis.Results: Using WGCNA and differential gene expression analysis, 29 differentially expressed genes were screened. The functional annotation analysis showed these genes to be mainly concentrated in heart trabecula formation, regulation of inflammatory response, collagen-containing extracellular matrix, and metalloendopeptidase inhibitor activity. Also, in the protein–protein interaction network analysis, 10 central genes were identified using Cytoscape's CytoHubba plug-in. The expression of CDH5, TEK, TIMP3, EDNRB, EPAS1, MYL9, SPARCL1, KLF4, and TGFBR3 in LUAD tissue was found to be lower than that in the normal control group, while the expression of MMP1 in LUAD tissue was higher than that in the normal control group. According to survival analysis, the low expression of MYL9 and SPARCL1 was correlated with poor overall survival in patients with LUAD. Finally, through the verification of the Oncomine database, it was found that the expression levels of MYL9 and SPARCL1 were consistent with the mRNA levels in LUAD samples, and both were downregulated.Conclusion: Two survival-related genes, MYL9 and SPARCL1, were determined to be highly correlated with the development of LUAD. Both may play an essential role in the development LUAD and may be potential biomarkers for its diagnosis and treatment in the future.

Download Full-text

Novel VWF Sequence Variations Identified in Normal Controls and Index Cases Enrolled in the TS Zimmerman Program for the Molecular and Clinical Biology of VWD (ZPMCB-VWD).

Blood ◽

10.1182/blood.v110.11.709.709 ◽

2007 ◽

Vol 110 (11) ◽

pp. 709-709 ◽

Cited By ~ 1

Author(s):

Daniel B. Bellissimo ◽

P.A. Christopherson ◽

S.L. Haberichter ◽

V.H. Flood ◽

J.C. Gill ◽

...

Keyword(s):

Normal Control ◽

Normal Control Group ◽

Control Group ◽

Normal Individuals ◽

Sequence Variations ◽

Clinical Biology ◽

Von Willebrand ◽

Index Cases ◽

Normal Controls

Abstract Von Willebrand disease (VWD) is caused by quantitative (types 1 and 3) and qualitative (type 2) defects in von Willebrand factor (VWF). The TS Zimmerman Program for the Molecular and Clinical Biology of VWD is a multinational Program Project established to further the study of VWD in the United States and to contrast these studies with the studies initiated previously in the EU and Canada. As one of the components of this study we sought further insight into the clinical expression and penetrance of established types of VWD by performing full gene DNA sequence analysis in VWD patients and normal controls. This report is an interim report of the first 50 index cases and 113 normal individuals recruited into this study. Twenty four of these index cases were found to have known mutations, four of which had a second new mutation, and 11 cases had 1 or 2 new mutations. In cases where mutations were identified, 46% of the identified mutations were new mutations that have not been reported in the Sheffield VWF Mutation Database. In 15 patients, no mutations were identified in the coding region, although analysis of the non-coding regions is still in progress. Five of the mutations were deletions, insertions, or nonsense mutations that have clear functional consequences. The other 12 mutations were missense mutations. Since VWF polymorphisms are not well characterized in all exons, we have also completed studies of the first 113 normal control individuals in our study. These are individuals without a bleeding history and in whom full VWF laboratory testing and VWF sequencing was also undertaken. Since some estimates in the EU and Canadian studies have determined the prevalence of VWF mutations varies by the severity of type 1 VWD patients, we wanted to determine the frequency of VWF variation in a normal population and determine if sequence variations correlate with VWF levels. There were three linked common polymorphims identified in normal African Americans that are discussed elsewhere and are not included in this present analysis. We found 19 new sequence variations in the normal control group of which three (2900G>A, 6554G>A, 7997C>T) were found individually in 4–6% of the normal control samples. In addition, in 12 normal control samples we identified 6 sequence variations that were previously reported as VWF mutations. Four were reported as type 1 mutations (2220 G>A, 3686T>G, 3692A>C, 6859C>T) and two as type 2N mutations (2451T>A, 2771G>A). The 2220G>A and 2451T>A mutations were seen in 6 normal controls (5%) and 5 of these 6 normal controls had both mutations. In another normal control, both 3686T>G and 3692A>C were identified. Although the reported prevalence of VWD is 1% or greater, the frequency of these mutations in our normal controls is higher than expected (as high as 5%). In our normal control group, the mean VWF:Ag concentration in the patients with polymorphisms/mutations did not differ from the normal control group as a whole and did not cluster on the lower end of the normal range. Thus, the data on our normal individuals suggest that VWF gene variation is considerable and that many mutations and polymorphisms remain to be identified. Differentiation of those that affect the diagnosis of VWD and/or hemorrhagic risk continues to be difficult.

Download Full-text

Nasal Cycle in Patients with Septal Deviation: Evaluation by Acoustic Rhinometry

American Journal of Rhinology ◽

10.2500/105065800782102681 ◽

2000 ◽

Vol 14 (3) ◽

pp. 171-174 ◽

Cited By ~ 9

Author(s):

Yeol-Woong Sung ◽

Min-Han Lee ◽

In-Jung Kim ◽

Dong-Woo Lim ◽

Ki-Sang Rha ◽

...

Keyword(s):

Normal Control ◽

Normal Subjects ◽

Normal Control Group ◽

Septal Deviation ◽

Control Group ◽

Cycle Duration ◽

Cross Sectional ◽

Nasal Cycle ◽

Narrow Side ◽

Normal Controls

The nasal cycle in patients with septal deviation was studied by acoustic rhinometric techniques. This study included 24 patients with anteriorly located septal deviations (mean age = 23.5), and 26 normal controls (mean age = 24.7). Data of MCA (minimum cross-sectional area) and NV (nasal volume), collected in 20-minute intervals, were plotted for each subject during 8 hours. Twenty of 24 patients (83%) with septal deviation and 20 of 26 normal subjects (77%) showed at least one complete cycle. Duration of the nasal cycle, which ranged from 100 minutes to 400 minutes, had no statistical difference between the septal deviation group (mean duration of 216 minutes) and the normal control group (mean duration of 227 minutes). The degrees of variation of MCA and NV, defined as Degree of Variation of MCA (%) = 100 (MCAmax – MCAmin)/MCAmax, Degree of Variation of NV (%) = 100 (NVmax – NVmin)/NVmax, which represent the percent change of MCA and NV throughout the study, showed no difference between the wide side and the narrow side, or between the septal deviation group and the normal control group. These findings suggest that the nasal cycle is relatively independent of peripheral anatomic factors for its generation. However, the amplitude of changes of MCA was greater in the wide side, and the sum of both MCAs tended to fluctuate in accordance with the fluctuation of MCA of the wide side. Thus, the nasal cycle seemed to be affected by septal deviation.

Download Full-text

Abnormal expression of Tie1 on the valves of great saphenous varicose vein

Phlebology The Journal of Venous Disease ◽

10.1258/phleb.2012.012018 ◽

2013 ◽

Vol 28 (2) ◽

pp. 93-100 ◽

Cited By ~ 3

Author(s):

Xin Wang ◽

Rong Zhao ◽

Changjian Liu ◽

Tong Qiao

Keyword(s):

Lower Extremity ◽

Western Blot ◽

Normal Control ◽

Varicose Vein ◽

Varicose Veins ◽

Normal Control Group ◽

Control Group ◽

Rt Pcr ◽

Venous Valves ◽

Distal Side

Objective To investigate the abnormal expressions of Tie1 on the valves of great saphenous varicose vein, and to discuss the relationship between the phenomenon and pathogenesis of varicose vein of lower extremity. Methods Varicose veins group 18 samples, normal control group 14 samples. Immunohistochemistry staining has investigated the expression of CD31 and Tie1 in the first valves of great saphenous veins. Semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR) has checked mRNA expression of Tie1. Western blot has checked the expression of Tie1 protein in venous valves. Results In normal control group valves, there was no difference between proximal and distal sides endothelium, which expressing CD31 in both valvar basement and valve cusp (positive endothelial cells [ECs] percentage: P > 0.05, P > 0.05). However, the endothelium of the proximal side demonstrates Tie1 stronger than distal side in valvar basement (positive ECs percentage: P < 0.05), which was not found at valve cusp (positive ECs percentage: P > 0.05). In varicose veins group, the endothelium of proximal side cells expresses CD31 weaker than distal side at both valvar basement and valve cusp (positive ECs percentage: P < 0.05, P < 0.05) besides the morphological alteration of valves. Moreover, it expresses Tie1 much weaker than diatal side (positive ECs percentage: P < 0.01). Semi-quantitative RT-PCR showed that valves of varicose veins group expressed Tie1 much weaker than the normal control group ( P < 0.01). Western blot could not detect the expression of Tie1 in venous valves. Conclusion The decreasing expression of Tie1 may play an important role in the pathogenesis of primary lower extremity varicose veins.

Download Full-text

The Serum Complement System in Children on Continuous Ambulatory Peritoneal Dialysis

Peritoneal Dialysis International ◽

10.1177/089686089301300310 ◽

1993 ◽

Vol 13 (3) ◽

pp. 214-218 ◽

Cited By ~ 7

Author(s):

Roel E. Reddingius ◽

Cornelis H. Schröder ◽

Mohamed R. Daha ◽

Leo A.H. Monnens

Keyword(s):

Renal Failure ◽

Peritoneal Dialysis ◽

Continuous Ambulatory Peritoneal Dialysis ◽

Normal Control ◽

Serum Levels ◽

Normal Control Group ◽

University Hospital ◽

Control Group ◽

Significant Difference ◽

Normal Controls

Objective During continuous ambulatory peritoneal dialysis (CAPD), the loss of complement factors via the dialysate may cause complement deficiencies. This hypothesis was tested in a group of children treated with CAPD. Design Classical (CH50) and alternative (AP50) complement activity and serum levels of factors C1 q, C3, C4, C3d, B, D, and P in CAPD patients were compared to normal controls and to children with preterminal renal failure. Setting Patients were seen in a university hospital; normal controls were seen in an outpatient clinic of a general hospital. Patients A group of 22 children on CAPD was compared to a normal control group of 44 children and to a group of 12 children with preterminal renal failure with a creatinine clearance below 25 mL/min/1.73 m2. Results CH50, AP50, C3, and B were not significantly different from the control group in both the CAPD and preterminal groups. Factors C1q (p=0.01) and C4, C3d, D, and P (p<0.001) were higher in the CAPD group in comparison to the normal control group. The factors D (p<0.001) and P (p=0.02) were also elevated in the preterminal group. For the measured factors there was no significant difference between the CAPD group and the preterminal group. Conclusions There is no deficiency of complement in children treated with CAPD. High levels of C3d and D can be explained by the reduction of their elimination by the kidney. The increased levels of the other factors are presumably due to increased synthesis in renal failure. This does not seem to be caused by CAPD.

Download Full-text

Study on the Burden of Abnormal Hematopoietic Clone of the Patients with Myelodysplastic Syndromes.

Blood ◽

10.1182/blood.v106.11.4899.4899 ◽

2005 ◽

Vol 106 (11) ◽

pp. 4899-4899

Author(s):

Zonghong Shao ◽

Huaquan Wang ◽

Jun Shi ◽

Yanran Cao ◽

Hong Liu ◽

...

Keyword(s):

Bone Marrow ◽

Serum Level ◽

Normal Control ◽

Myelodysplastic Syndromes ◽

Bone Marrow Cells ◽

Normal Control Group ◽

Haematopoietic Stem Cell ◽

Control Group ◽

Normal Controls ◽

Marrow Cells

Abstract Background Myelodysplastic syndromes (MDS) is a group of clone haematopoietic stem cell diseases. The burden of abnormal hematopoietic clone plays key roles in the development of this disease and needs to be further studied quantitively. Methods The ratio of the counted bone marrow cells with abnormal chromosomes to the total counted bone marrow cells was regarded as the index of MDS clone burden. The disease severity related parameters including white cell count, hemoglobin, platelet count, lactate dehydrogenase level, bone marrow blast, myeloid differentiation index, the ratio of cFU-GM to CFU-GM, micromegakaryocyte, transfusion, IL-2, TNF, CD4+ and CD8+ T cells of MDS patients were assayed and the correlations between those parameters and MDS clone burden were also analysed. Results The clone burden of MDS patients was (67.4±36.2)%. MDS clone burden correlated positively with bone marrow blasts(r =0.483, P=0.012), negatively with hemoglobin level(r = −0.445, P= 0.023); The number of blasts, hemoglobin and erythocytes in high clone burden(>50%) and low clone burden(≤50%) groups were (7.78±5.51)% and (3.45±3.34)%(P=0.035), (56.06±14.28)g/L and (76.40±24.44)g/L(P=0.013), (1.82±0.12)×1012/L and (2.32±0.21)×1012/L(P=0.034)respectively. CD4+ T lymphcytes of MDS patients and normal controls were (274.18±71.85)×106/L and (454.82±205.88)×106/L(P=0.012)respectively. CD8+ T lymphcytes of MDS patients and normal controls were (240.45±150.01)×106/L an (305.27±145.14)×106/L(P=0.317)respectively. The serum level of interleukin 2 of MDS patients and normal control group were (6.29±3.58)ng/ml and (3.11±1.40)ng/ml (P=0.002) respectively. The serum level of tumor necrosis factor of MDS patients and normal control group were (2.42±1.79)ng/ml and (1.68±0.69)ng/ml(P=0.124)respectively. The ratio of CD4 to CD8 in high clone burden MDS patients was (1.90±0.52), and that in low clone burden patients was (0.97±0.44)(P=0.022). Conclusion The quantitive clonal karyotype abnormalities and deficient T cell immunity are important parameters for evaluating MDS severeity and prediciting it’s progression.

Download Full-text

Evaluation of E2F3 and survivin expression in peripheral blood as potential diagnostic markers of prostate cancer

Turkish Journal of Biochemistry ◽

10.1515/tjb-2019-0323 ◽

2020 ◽

Vol 45 (5) ◽

pp. 525-532

Author(s):

Ahmed M. Wadaa Allah ◽

Fatma F. Abdel Hamid ◽

Ahmed F. Soliman ◽

Noha Ibrahim ◽

Ibrahim Malash ◽

...

Keyword(s):

Gene Expression ◽

Prostate Cancer ◽

Normal Control ◽

Peripheral Blood ◽

Normal Control Group ◽

Control Group ◽

Relative Gene Expression ◽

Expression Levels ◽

Relative Gene ◽

Gene Expression Levels

AbstractBackgroundProstate cancer (PC) incidence has risen globally. As there are no current independent biomarkers with high diagnostic efficiency to detect PC, this study was performed to investigate the relative gene expression levels of E2F3 and survivin in the whole blood of PC, benign prostate hyperplasia (BPH), and normal control individuals and to explore their diagnostic value.Material and methodsParticipants of the study were divided into three groups; normal control group (n=25), BPH patients (n=25), and PC patients (n=75). The E2F3 and survivin gene expression levels were assessed using real-time qPCR in addition to the measurement of free and total levels of prostate-specific antigen (PSA) using electrochemiluminescence assays.ResultsSurvivin relative gene expression was over-expressed in PC and BPH patients compared to the normal control group, whereas, E2F3 did not differ significantly among the studied groups. Compared to PSA, E2F3 and survivin mRNA expression levels had lower diagnostic efficacy to differentiate PC from normal and BPH individuals with an area under curve (AUC) of 0.471 and 0.727, respectively. Further, survivin expression level was associated with increased the risk of PC.ConclusionSurvivin and E2F3 relative expression levels in peripheral blood had low diagnostic performance to detect PC and individuals with high survivin expression levels may have higher risk to develop PC.

Download Full-text

Hepatotoxicity and Histological Evaluation of Aqueous and Methanolic Leaf Extracts of Thaumatococcus Daniellii and Alchornea Cordifolia in Wistar Rat Models

Modern Health Science ◽

10.30560/mhs.v1n2p42 ◽

2019 ◽

Vol 1 (2) ◽

pp. p42

Author(s):

Service @ Ideasspread.org ◽

Okafor I. J. ◽

Nweke E. O. ◽

Ewa O.

Keyword(s):

Normal Control ◽

Wistar Rat ◽

Normal Control Group ◽

Histological Evaluation ◽

Control Group ◽

Significant Elevation ◽

Leaf Extracts ◽

Group Iii ◽

Methanolic Extracts ◽

Group I

This study was carried out to ascertain the hepatotoxic potential of T.daniellii (T.d) and A. cordifolia (A.c). Investigations were conducted using standard methods. Oral administration of 200mg/kg aqueous leaf extracts of T.daniellii caused a non-significant increase in the activity of ALT (5.43±0.60IU/L), AST (16.93±0.26 IU/L) and ALP (160.70±1.04 IU/L) compared to the values recorded on the normal control (group I) ALT (3.84±0.16 IU/L), AST (14.19±0.52 IU/L) and ALP (157.26±0.64 IU/L). Group III administered with 200mg/kg methanolic leaf extract of T. daniellii manifested a significant elevation in the activity of ALT (13.15±0.89 IU/L), AST (22.84±0.38 IU/L) and ALP (170.40±0.44 IU/L) compared to the normal control. Similarly, groups IV and V which were orally administered with 200mg/kg aqueous and methanolic leaf extracts of A. cordifolia showed significant increase in the activity of ALT (6.32±0.33U/L), AST (17.70±0.030U/L) and ALP (161.13±0.09U/L) and ALT (7.55±0.59U/L), AST (19.35±0.26U/L) and ALP (165.38±0.35U/L) respectively compared to the values recorded on the control (group I). In conclusion, drug development protocols involving T. daniellii leaf should preferably use water as an ideal solvent. On the other hand, the hepatotocity associated with both aqueous and methanolic extracts of A. cordifolia could imply the presence of hepatotoxins in the leaf of the said plant.

Download Full-text